Affymax is a Palo Alto, Calif.-based biopharmaceutical company. The company’s focus is on discovering, developing and delivering innovative therapies to improve the lives of patients suffering with kidney disease and other serious, often life-threatening illnesses. OMONTYS, the company’s first marketed products, was approved by the U.S. FDA in March 2012. For more information, visit the company’s Web site at www.affymax.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: